MedTrace Logo

Effects of Caffeine on Cerebral Blood Flow

NCT05866848 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-05-19

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate in clinically healthy young people if:

* after caffeine ingestion, there are variations in blood velocity of the middle cerebral arteries (VMCA),
* this variation is dependent on the administered dose.

Transcranial Doppler ultrasonography was used to record blood VMCA in three groups of 15 clinically healthy young adults each - no caffeine, low caffeine (45 mg) and high caffeine group (120 mg). Transcranial Doppler ultrasonography provided simultaneous bilateral VMCA measurements while subjects performed functional tests (hyperventilation and hypoventilation orders) and three cognitive activities (Test 1, short-term remembering, Test 2, solving a vocabulary problem, and Test 3, solving a math problem) each in 31-second tests with 1-minute rest between them. Participants were assessed before and 30 minutes after caffeine ingestion.

Conditions

  • Cardiovascular System

Interventions

OTHER

Placebo

Flour capsules as a placebo.

OTHER

Anhydrous caffeine (45mg)

Capsules dosed with 45mg of anhydrous caffeine.

OTHER

Anhydrous caffeine (120mg)

Capsules dosed with 120mg of anhydrous caffeine.

Sponsors & Collaborators

  • Escola Superior de Tecnologia da Saúde de Coimbra

    lead OTHER

Principal Investigators

  • Hélder Santos, PhD · Polytechnic Institute of Coimbra - Coimbra Health School

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05866848 on ClinicalTrials.gov